Dr. Daniel De Carvalho to Collaborate with Pfizer on Cancer Immunotherapy Research

MBP scientist Dr. Daniel De Carvalho has embarked on a collaborative drug discovery research program with Pfizer’s Center for Therapeutic Innovation (CTI). The project involves preclinical drug development leveraging Dr. Carvalho’s expertise in immunotherapy. According to UHN, the project aims to ‘screen, identify and optimize potential drug candidates that trigger the body’s own immune system to kill cancer cells in a novel manner’.

Learn more about this collaborative research project on the UHN Technology Development Site.